Provectus Pharmaceuticals to Host Investor Conference Call on November 23, 2010 at 11:30 A.M. EST

-Will Discuss Recent Clinical Trial Results-

KNOXVILLE, Tenn.--(BUSINESS WIRE)-- Provectus Pharmaceuticals, Inc. (OTC BB: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, will be hosting an investor conference call on Tuesday, November 23, 2010 at 11:30 a.m., EST, to discuss the positive preliminary data from its Phase 2 clinical trial of PV-10 for metastatic melanoma, that were recently presented at the Melanoma 2010 Congress in Sydney, Australia, and to provide an update on the Company’s progress. Participating in the call will be Peter Culpepper, Chief Operating Officer and Chief Financial Officer, and Eric Wachter, Ph.D. – Executive Vice President.

Those who wish to participate in the conference call may telephone 877-407-8291 from the U.S.; international callers may telephone 201-689-8345, approximately 15 minutes before the call. There will be a simultaneous webcast on www.pvct.com under the “Investors” tab of the website. A digital replay will be available by telephone approximately two hours after the call’s completion for two weeks, and may be accessed by dialing 877-660-6853 from the U.S. or 201-612-7415 for international callers, Acct #381; Replay ID #361268. The replay will also be on the website under “Investors” at www.pvct.com for one month.

About Provectus Pharmaceuticals, Inc. (www.pvct.com)

Provectus Pharmaceuticals specializes in developing oncology and dermatology therapies. Its novel oncology drug PV-10 is designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing systemic side effects. Its oncology focus is on melanoma, breast cancer and metastatic cancers of the liver. The Company has received orphan drug designation from the FDA for its melanoma indication. Its dermatological drug PH-10 also targets abnormal or diseased cells, with the current focus on psoriasis and atopic dermatitis. Provectus has recently completed Phase 2 trials of PV-10 for metastatic melanoma, and of PH-10 as a topical treatment for atopic dermatitis and psoriasis. Information about these and the Company's other clinical trials can be found at the NIH registry, www.clinicaltrials.gov. For additional information about Provectus please visit the Company's website at www.pvct.com or contact Porter, LeVay & Rose, Inc.

FORWARD-LOOKING STATEMENTS: The forward-looking statements contained herein are subject to certain risks and uncertainties that could cause actual results to differ materially from those reflected in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date hereof. The company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date thereof.



CONTACT:

Provectus Pharmaceuticals, Inc.
Peter R. Culpepper, CFO
866-594-5999 #30
or
Porter, LeVay & Rose, Inc.
Marlon Nurse, DM, VP – Investor Relations
Bill Gordon, SVP – Media Relations
212-564-4700

KEYWORDS:   United States  North America  Tennessee

INDUSTRY KEYWORDS:   Surgery  Health  Biotechnology  Clinical Trials  Hospitals  Pharmaceutical  Other Health  General Health

MEDIA:

Suggested Articles

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.

At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.